Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Evenamide
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Recipient : Newron Pharmaceuticals
Deal Size : $122.7 million
Deal Type : Licensing Agreement
Newron and EA Pharma Sign License for Evenamide in Japan and Asian Regions
Details : Under the terms of the license agreement, EA will develop and commercialize Newron’s innovative NW-3509 (evenamide) for treatment-resistant schizophrenia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $46.0 million
December 13, 2024
Lead Product(s) : Evenamide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Recipient : Newron Pharmaceuticals
Deal Size : $122.7 million
Deal Type : Licensing Agreement
Lead Product(s) : NSHO-101
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Ensho Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for IBD
Details : Ensho has the right to develop, manufacture, and commercialize a portfolio of oral alpha-4 beta-7 integrin integrin inhibitors, EA1080 (NSHO-101), globally, excluding certain Asian jurisdictions.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 27, 2024
Lead Product(s) : NSHO-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Ensho Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : NSHO-101
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Ensho Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
EA Pharma and Ensho Sign License Agreement for EA1080, α4β7 Integrin Antagonist
Details : Under the terms of the license agreement, Ensho will conduct global clinical studies for EA1080, which is being evaluated in the early-stage clinical studies for inflammatory bowel disease.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 27, 2024
Lead Product(s) : NSHO-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Ensho Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Macrogol
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Mochida Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MOVICOL® HD is a high dose formulation of existing “MOVICOL® LD”, the first polyethylene glycol indicated for treatment of chronic constipation1) in Japan. MOVICOL® HD contains the same active ingredients in double the quantity of MOVICOL® LD per...
Product Name : Movicol HD
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2022
Lead Product(s) : Macrogol
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Mochida Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carotegrast Methyl
Therapeutic Area : Immunology
Study Phase : Phase III
Recipient : Kissei Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Primary endpoint was achieved in Phase III clinical study (AJM300/CT3) of AJM300 (nonproprietary name: carotegrast methyl), which EA Pharma and Kissei Pharmaceutical have developed for treatment of ulcerative colitis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2021
Lead Product(s) : Carotegrast Methyl
Therapeutic Area : Immunology
Highest Development Status : Phase III
Recipient : Kissei Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Risedronate Sodium
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Actonel (risedronate sodium hydrate) tablet act as inhibits osteoclasts, which is indicated for the treatment of Paget’s disease and treatment and prevention of postmenopausal osteoporosis.
Product Name : Actonel
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2020
Lead Product(s) : Risedronate Sodium
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elobixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Recipient : Yokohama City University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2020
Lead Product(s) : Elobixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Recipient : Yokohama City University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EA1080
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2020
Lead Product(s) : EA1080
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : E3112
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 22, 2019
Lead Product(s) : E3112
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : E6011
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of E6011 in Participants With Active Crohn's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 07, 2018
Lead Product(s) : E6011
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable